Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on November 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 24,650 share…
Solo un extracto — este editor licencia su texto. Lea el comunicado completo en la fuente.
Plan Gratis · Plus 29 CA$ o Pro 99 CA$/mes


